Petcu M, Dias J P, Ongali B, Thibault G, Neugebauer W, Couture R
Département de Physiologie, Faculté de Médecine, Université de Montréal, C.P. 6128, Succursale Centre-ville, Montréal, Québec, Canada H3C 3J7.
Int Immunopharmacol. 2008 Feb;8(2):188-96. doi: 10.1016/j.intimp.2007.09.009. Epub 2007 Sep 29.
Kinin B1 and B2 receptor (R) gene expression (mRNA) is increased in the sensory system after peripheral nerve injury. This study measured the densities of B1R and B2R binding sites in the spinal cord and dorsal root ganglia (DRG) by quantitative autoradiography, and evaluated the effects of two selective non-peptide antagonists at B1R (LF22-0542) and B2R (LF16-0687) on pain behavior after partial ligation of the left sciatic nerve. Increases of B1R binding sites were seen in superficial laminae of the ipsi- and contralateral spinal cord at 2 and 14 days while B2R binding sites were increased on the ipsilateral side at 2 days and on both sides at 14 days. In DRG, B1R and B2R binding sites were significantly increased at 2 days (ipsilateral) and 14 days on both sides. Whereas tactile allodynia started to develop progressively from 2 to 25 days post-ligation, the occurrence of cold allodynia and thermal hyperalgesia became significant from day 8 and day 14 post-ligation, respectively. At day 21 after sciatic nerve ligation, thermal hyperalgesia was blocked by LF22-0542 (10 mg/kg, s.c.) and LF16-0687 (3 mg/kg, s.c.), yet both antagonists had no effect on tactile and cold allodynia. Data highlight the implication of both kinin receptors in thermal hyperalgesia but not in tactile and cold allodynia associated with peripheral nerve injury. Hence LF22-0542 and LF16-0687 present therapeutic potential for the treatment of some aspects of neuropathic pain.
在周围神经损伤后,激肽B1和B2受体(R)基因表达(mRNA)在感觉系统中增加。本研究通过定量放射自显影法测量脊髓和背根神经节(DRG)中B1R和B2R结合位点的密度,并评估两种选择性非肽类拮抗剂B1R(LF22 - 0542)和B2R(LF16 - 0687)对左侧坐骨神经部分结扎后疼痛行为的影响。在第2天和第14天,同侧和对侧脊髓浅层中B1R结合位点增加,而B2R结合位点在第2天同侧增加,第14天两侧均增加。在DRG中,第2天(同侧)和第14天两侧B1R和B2R结合位点均显著增加。结扎后触觉异常性疼痛从第2天到第25天逐渐发展,冷异常性疼痛和热痛觉过敏分别从结扎后第8天和第14天开始显著出现。坐骨神经结扎后第21天,热痛觉过敏被LF22 - 0542(10 mg/kg,皮下注射)和LF16 - 0687(3 mg/kg,皮下注射)阻断,但两种拮抗剂对触觉和冷异常性疼痛均无影响。数据突出了两种激肽受体在热痛觉过敏中的作用,而不是在与周围神经损伤相关的触觉和冷异常性疼痛中的作用。因此,LF22 - 0542和LF16 - 0687在治疗某些神经性疼痛方面具有治疗潜力。